#eloratzp

2 stories

#eli lilly #amylin medications #cagrisema #drug valuation #eloralintide #fda approval #glp-1 drugs #mounjaro #novo #novo nordisk #obesity treatment #petrelintide

New weight-loss drugs promise fewer side effects
Amylin-based medications show promise as alternatives to GLP-1 drugs, causing less nausea and stomach trouble while delivering comparable weight loss.
TIME · 2m
Eli Lilly's obesity bet hinges on September 30 data
A two-drug combo could justify Lilly's trillion-dollar valuation, but the mid-stage trial results will determine if it's a breakthrough or an expensive gamble.
24/7 Wall St. · 1m